What this study adds
Patients ineligible for Phase III trials of direct oral
anticoagulants, yet receiving anticoagulants for non-valvular atrial
fibrillation, exhibited worse outcomes compared to eligible patients.
The study points to a potential discrepancy between clinical evidence
and real-world practice regarding the safety and effectiveness of
anticoagulants.